Investigational immunotherapeutic increased bladder cancer survival

November 18th, 2015 | Posted by admin in Uncategorized

Among patients with metastatic bladder cancer that had progressed after platinum-based chemotherapy, those who received an investigational, personalized peptide cancer vaccine and best-supportive care had extended overall survival compared with those who received best-supportive care alone, according to results from a randomized, phase II clinical.
Source: Health Medicine Science Daily

You can follow any responses to this entry through the RSS 2.0 You can leave a response, or trackback.

Leave a Reply

Your email address will not be published. Required fields are marked *